iGene Applies for Phase 1/2a Clinical Trial Plan of COVID-19 Vaccine Booster
[Asia Economy Reporter Minji Lee] iGene announced on the 5th that it has applied for a Phase 1/2a clinical trial plan to verify the safety, tolerability, and immunogenicity of its mRNA-based COVID-19 vaccine (EG-COVID) booster shot in Australia.
Hot Picks Today
Even with High Oil Price Relief Payment, Additional 300,000 Won Per Person to Be Provided... Applications Open from the 18th in This Region
- "Invested 95% in Hynix and Reached 10 Billion Won"... Japanese Investor's Proof Post Goes Viral
- "Why Is the Korean Stock Market Surging?"... Even Italy Is Astonished by the KOSPI Rally
- "You Don't Need to Go to the Gym": The Best Exercises for Lowering Hypertension
- "That Thing Wakes Up Every Night" ... Suspicious Object Covers Rural Village
The company stated, "After completing Phase 1 of the Phase 1/2a clinical trial in Australia, Phase 2a, which will be conducted on 100 subjects, is planned to take place in Australia and the Republic of South Africa." It added, "We plan to apply for the clinical trial plan in the Republic of South Africa as soon as possible." Furthermore, it explained, "Depending on the evaluation results of safety, tolerability, and immunogenicity confirmed during this clinical process, we plan to proceed to the next phase of clinical trials."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
